Greenwich LifeSciences, Inc. GLSI
$18.70
+35.90%
at last close
Market Cap$201.97 million
P/E Ratio—
Div Yield—
Volume1.11M
52-Week Range
$7.78$34.10
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $70.00 (+274.3% upside)
Key Stats
- Today's Range
- $15.73 – $19.28
- 50-Day Range
- $13.38 – $20.31
- 52-Week Range
- $7.78 – $34.10
- Volume
- 1.11 million shs
- Average Volume
- 169K shs
- Market Cap
- $201.97 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.02%
- Days to Cover
- 1.00
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Related Stocks
Compare head-to-head: GLSI vs LLY·GLSI vs JNJ·GLSI vs ABBV·GLSI vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
